Skip to main content
Equibles
NMRA logo

NMRA · Neumora Therapeutics, Inc.

Track NMRA — free

Use NMRA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NMRA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.04 -0.10 (-8.77%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“While the Company expects to be able to obtain additional funding, the current available cash and cash equivalents will not be sufficient to fund the Company’s operating plans for at least twelve months from the issuance date of these condensed consolidated financial statements. Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$195.41M
Shares
187.90M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.04 Open$1.16 Day$1.02–1.16 52W close$0.92–3.59 Avg vol 30d745K Short int8.0M · 4.3% float · 10.2d Short vol29% Last earningsMar 30, 2026 DataSep 2023–Sep 2026 Filing10-Q · Aug 14

Up next

Latest filing: 10-Q
filed Aug 14, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$212.75M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+14.5%
Year over year · more shares
Price change (1Y)
-30.1%
Trailing year
Short interest
4.3%
Latest settlement · 10.2 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bearish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.60
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −49%
below
Price vs 50-day avg −33%
below
RSI (14) 26
oversold
MACD trend Negative
52-week position 5%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −40%
trailing
6-month return −59%
trailing
YTD return −42%
this year
Relative strength −76%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Distributing
-2% holders QoQ · +28 funds added
Insider flow Distributing
Net -$701.6K over 90 days · 100% sells
Short interest Rising
4.27% of float · ▲ +0.5% MoM · 10.2 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
112 holders — mid 3-yr range
Squeeze score 61
elevated · 0–100
Fundamentals
Fair
EPS growth +5%
Y/Y
Free cash flow $-206.6M
Balance sheet $68.0M
net cash
Quant / Vol
risk profile
Very High
Volatility 126%
annualized · 1-yr
Max drawdown −75%
past year
ATR 10.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−49% Bearish
Price vs 50-day avg
−33% Bearish
RSI (14)
26 Neutral
MACD trend
Negative Bearish
52-week position
5% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Distributing
-2% holders QoQ · +28 funds added
Insider flow Distributing
Net -$701.6K over 90 days · 100% sells
Short interest Rising
4.27% of float · ▲ +0.5% MoM · 10.2 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
112 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 5% Range high $4
vs 200-day avg -49% vs 50-day avg -33%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NMRA
Neumora Therapeutics, Inc.
this stock
$195.41M -41.9% — — 4.3%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.64B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.22B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
112
% held
41.8%
Net QoQ
+6.2M sh
Top holder
Siren, L.L.C.
Held Float
View
Held by Funds
Fund positions
77
View
Short & Settlement
Short Interest Rising
Shares short
8.0M
Days to cover
10.2d
Change
+36.5K sh
View
Short Volume
Short vol %
29%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
1.3K
Value
$2.2K
As of
Aug 13, 2026
View
Off-Exchange
Off-exchange %
39.1%
Week of
Aug 3, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$701.6K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Financials
Financials
Net income (FY)
$-236.9M
EPS diluted
$-1.45
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 14, 2026
This year
14
View
Proposed Sales
Value
$66.4K
Shares
41.6K
Filed
Aug 21, 2026
View
Exempt Offerings
Offering
$474.4M
Filed
Jan 3, 2023
View
Earnings & Events
Earnings Calls
Last call
Apr 13, 2026
View

Performance

5D 20D 120D MTD YTD
NMRA -23.0% -39.9% -58.6% -21.8% -41.9%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -21.8% -38.1% -76.4% -21.4% -54.0%
Key facts CIK 1885522 CUSIP 640979100 13F (30d) 45 filings 45 filers Visit website Investor relations